Health economics and outcomes research, commonly called HEOR, is a discipline that evaluates whether medical treatments are worth their cost by measuring both their real-world results and their economic impact. It sits at the intersection of clinical science, economics, and patient experience, and it plays a central role in decisions about which drugs get covered by insurance, how they’re priced, and whether health systems adopt them. If you’ve ever wondered how a country or insurance plan decides that a new cancer drug is “worth it” at $150,000 a year but not at $300,000, that decision almost certainly involved HEOR data.
The Two Halves of HEOR
The name itself reveals the two core components. Health economics focuses on comparing the costs of different treatments relative to their benefits. Outcomes research focuses on measuring what actually happens to patients, not just in controlled clinical trials but in everyday medical practice. Together, these two disciplines give decision-makers a fuller picture than either could alone. A drug might perform beautifully in a trial of 500 carefully selected patients, but HEOR asks: does it still work in the broader population, and is the improvement it delivers proportional to what it costs?
How Treatments Get Evaluated Economically
Health economists use several types of formal analysis to compare treatments. The most common ones differ mainly in how they measure the “benefit” side of the equation.
- Cost-effectiveness analysis compares two or more treatments based on cost per unit of health gained, measured in straightforward terms like life-years gained or cases of disease prevented.
- Cost-utility analysis is a specific form of cost-effectiveness analysis that uses a metric called the quality-adjusted life year (QALY), which accounts for both how long a person lives and how well they live. This is the most widely used approach in formal technology assessments.
- Cost-benefit analysis converts both costs and health outcomes into monetary terms, essentially asking whether the dollar value of the health gained exceeds the dollar cost of the treatment.
- Cost-minimization analysis applies when two treatments produce equivalent health results, and the question is simply which one costs less.
Of these, cost-utility analysis dominates modern HEOR because QALYs allow comparisons across completely different diseases. A QALY provides a common yardstick: you can weigh a heart attack prevention drug against a depression treatment against a surgical technique, all on the same scale.
What a QALY Actually Measures
A quality-adjusted life year combines quantity and quality of life into a single number. It’s calculated by multiplying the time spent in a given health state by a quality score ranging from 0 (death) to 1 (perfect health). So one year lived in perfect health equals 1 QALY, while one year lived at a quality score of 0.5 equals 0.5 QALYs. This lets analysts capture the reality that simply being alive longer isn’t the same as living well.
Different countries and organizations set different thresholds for how much they’re willing to pay per QALY gained. In the United States, the Institute for Clinical and Economic Review (ICER) uses benchmarks of $100,000 and $150,000 per QALY to estimate value-based prices for new drugs. A recent joint statement from the American Heart Association and American College of Cardiology recommended $120,000 per QALY as a cost-effectiveness threshold for clinical guidelines. In England and Wales, the National Institute for Health and Care Excellence (NICE) typically uses a lower range of £20,000 to £30,000 per QALY, though it allows higher thresholds for end-of-life treatments (£50,000) and rare diseases (up to £300,000).
Where Outcomes Research Fits In
The outcomes side of HEOR measures what patients actually experience. This goes well beyond the survival and lab-value endpoints of traditional clinical trials. Patient-reported outcome measures (PROMs) capture symptoms, physical functioning, and quality of life directly from patients themselves. Patient-reported experience measures (PREMs) capture how patients perceive the care process: communication with providers, shared decision-making, the hospital environment. PROMs help clinicians tailor treatment and catch problems early, while PREMs drive quality improvement by highlighting gaps in how care is delivered.
Outcomes research also draws heavily on real-world evidence, which comes from sources like electronic health records, insurance claims databases, and clinical registries. Randomized controlled trials remain the gold standard for establishing whether a treatment works, but they enroll highly selective patients under tightly controlled conditions. Real-world data captures what happens when treatments are used in broader, messier populations that include patients with multiple health conditions, varying disease severity, and different demographic backgrounds. In some cases, real-world evidence has shown treatment benefits greater than those estimated in clinical trials, precisely because it reflects more diverse patients and typical practice settings.
How HEOR Shapes Drug Pricing and Access
HEOR data is central to the process of getting a new drug covered by insurance plans and government health systems. In the United States, pharmaceutical companies submit HEOR evidence as part of formal dossiers reviewed by pharmacy and therapeutics committees at insurance plans. These committees weigh safety and efficacy first, but surveys of decision-makers show that net cost, head-to-head comparisons with existing treatments, and outcomes data are considered very or extremely important by roughly 83 to 90 percent of committee members.
This is where the concept of market access comes in. Pharmaceutical companies employ HEOR specialists specifically to build the economic and outcomes case for their products. The goal is to demonstrate that a treatment delivers enough value, relative to its price, to justify placement on an insurance formulary. Increasingly, payers are also exploring outcomes-based contracts, where the price a manufacturer receives is tied to how well the drug actually performs in the real world. These contracts use HEOR data as their foundation, shifting some financial risk from the payer to the manufacturer.
Who Works in HEOR
HEOR is a distinct career path that spans pharmaceutical companies, consulting firms, academic institutions, and government agencies. The field draws from several disciplines, including epidemiology, biostatistics, health policy, and pharmacoeconomics. Day-to-day work varies by role but generally falls into a few categories.
Outcomes researchers design and conduct studies on medical interventions, measuring survival rates, healthcare costs, and patient-reported outcomes like quality of life and satisfaction. Health economists build models to estimate cost-effectiveness and budget impact, often working extensively in spreadsheet-based modeling tools and statistical software like R, Stata, or SAS. Market access professionals translate HEOR findings into strategic arguments for payers and regulators, creating evidence summaries that demonstrate a product’s value. Across all these roles, the ability to perform systematic literature reviews, analyze large datasets, and communicate findings clearly through data visualization is essential.
HEOR professionals typically hold advanced degrees. The field has grown substantially as healthcare systems worldwide face increasing pressure to justify spending, making the ability to quantify the value of medical interventions one of the more in-demand skill sets in the health sciences.